Inside information - strategic collaboration and license agreement with roche
Filed with HKEX · Stock code 3692 · · 2 pages · English
Summary by 6ix AI
Hansoh Pharmaceutical Group Company Limited has announced a strategic collaboration and license agreement with Roche, focusing on a portfolio of Antibody-Drug Conjugate programs. Under the agreement, Hansoh will lead early development up to Phase Ia clinical trials, while Roche will handle further global development outside certain regions. Hansoh is set to receive significant upfront payments and potential milestone payments exceeding a substantial amount, along with royalties on future sales.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Hansoh Pharmaceutical Group Company Limited on 6ix
Earlier from Hansoh Pharmaceutical
- Voluntary announcement - marketing authorization application of Aumolertinib in the EU resubmitted and validated by the EMA
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement - update on the marketing authorization status of aumolertinib in the EU
- Voluntary announcement - biologics license application of risvutatug rezetecan for injection (HS-20093) for osteosarcoma accepted by the nmpa
- Notification letter to non-registered holders and request form
Follow Hansoh Pharmaceutical into a list and get an email when it puts out news.
Follow Hansoh Pharmaceutical